Anti-CD20 antibody therapy for B-cell lymphomas
DG Maloney - New England Journal of Medicine, 2012 - Mass Medical Soc
DG Maloney
New England Journal of Medicine, 2012•Mass Medical SocA 62-year-old man receives a diagnosis of diffuse large B-cell lymphoma; treatment with a
regimen including the anti-CD20 antibody rituximab is recommended. Rituximab has been
shown to improve progression-free survival when added to standard chemotherapy
regimens for lymphoma.
regimen including the anti-CD20 antibody rituximab is recommended. Rituximab has been
shown to improve progression-free survival when added to standard chemotherapy
regimens for lymphoma.
A 62-year-old man receives a diagnosis of diffuse large B-cell lymphoma; treatment with a regimen including the anti-CD20 antibody rituximab is recommended. Rituximab has been shown to improve progression-free survival when added to standard chemotherapy regimens for lymphoma.
The New England Journal Of Medicine